Differential association between S100A4 levels and insulin resistance in prepubertal children and adult subjects with clinically severe obesity.


Por: Taxerås SD, Galán M, Campderrós L, Piquer-Garcia I, Pellitero S, Martínez E, Puig R, Lucena I, Tarascó J, Moreno P, Balibrea J, Bel J, Murillo M, Martínez M, Ramon-Krauel M, Puig-Domingo M, Villarroya-Gombau F, Lerin C and Sánchez-Infantes D

Publicada: 1 feb 2020 Ahead of Print: 2 dic 2019
Resumen:
OBJECTIVES: S100A4 has been recently identified as an adipokine associated with insulin resistance (IR) in adult subjects with obesity. However, no data about its levels in children with obesity and only a few approaches regarding its potential mechanism of action have been reported. To obtain a deeper understanding of the role of S100A4 in obesity, (a) S100A4 levels were measured in prepubertal children and adult subjects with and without obesity and studied the relationship with IR and (b) the effects of S100A4 in cultured human adipocytes and vascular smooth muscle cells (VSMCs) were determined. METHODS: Sixty-five children (50 with obesity, age 9.0 ±1.1 years and 15 normal weight, age 8.4 ±0.8 years) and fifty-nine adults (43 with severe obesity, age 46 ±11 years and 16 normal weight, age 45 ±9 years) were included. Blood from children and adults and adipose tissue samples from adults were obtained and analysed. Human adipocytes and VSMC were incubated with S100A4 to evaluate their response to this adipokine. RESULTS: Circulating S100A4 levels were increased in both children (P = .002) and adults (P < .001) with obesity compared with their normal-weight controls. In subjects with obesity, S100A4 levels were associated with homeostatic model assessment-insulin resistance (HOMA-IR) in adults (ßstd = .42, P = .008) but not in children (ßstd = .12, P = .356). Human adipocytes were not sensitive to S100A4, while incubation with this adipokine significantly reduced inflammatory markers in VSMC. CONCLUSIONS: Our human data demonstrate that higher S100A4 levels are a marker of IR in adults with obesity but not in prepubertal children. Furthermore, the in vitro results suggest that S100A4 might exert an anti-inflammatory effect. Further studies will be necessary to determine whether S100A4 can be a therapeutic target for obesity.

Filiaciones:
Taxerås SD:
 Department of Endocrinology and Nutrition Germans Trias i Pujol Research Institute Barcelona Spain

Galán M:
 Institut de Recerca del Hospital de la Santa Creu i Sant Pau-Programa ICCC Barcelona Spain

 CIBER de Enfermedades Cardiovasculares (CIBERCV), ISCIII Madrid Spain

Campderrós L:
 Department of Biochemistry and Molecular Biology, Institute of Biomedicine University of Barcelona Barcelona Spain

 Biomedical Research Center (Red Fisiopatología de la Obesidad y Nutrición) (CIBEROBN), ISCIII Madrid Spain

Piquer-Garcia I:
 Department of Endocrinology and Nutrition Germans Trias i Pujol Research Institute Barcelona Spain

Pellitero S:
 Department of Endocrinology and Nutrition Germans Trias i Pujol Research Institute Barcelona Spain

 Biomedical Research Center (Red Fisiopatología de la Diabetes y enfermedades metabólicas) (CIBERDEM), ISCIII Madrid Spain

Martínez E:
 Department of Endocrinology and Nutrition Germans Trias i Pujol Research Institute Barcelona Spain

Puig R:
 Department of Endocrinology and Nutrition Germans Trias i Pujol Research Institute Barcelona Spain

Lucena I:
 Department of Endocrinology and Nutrition Germans Trias i Pujol Research Institute Barcelona Spain

Tarascó J:
 Department of Surgery Germans Trias i Pujol Research Institute Barcelona Spain

Moreno P:
 Department of Surgery Germans Trias i Pujol Research Institute Barcelona Spain

Balibrea J:
 Metabolic and Bariatric Surgery Unit, EAC-BS Center of Excellence Vall d'Hebron University Hospital Barcelona Spain

Bel J:
 Department of Pediatric Germans Trias i Pujol Research Institute Barcelona Spain

Murillo M:
 Department of Pediatric Germans Trias i Pujol Research Institute Barcelona Spain

Martínez M:
 Department of Pediatric Germans Trias i Pujol Research Institute Barcelona Spain

Ramon-Krauel M:
 Endocrinology Department Institut de Recerca Sant Joan de Déu Barcelona Spain

 Hospital Sant Joan de Déu Barcelona Spain

Puig-Domingo M:
 Department of Endocrinology and Nutrition Germans Trias i Pujol Research Institute Barcelona Spain

 Biomedical Research Center (Red Fisiopatología de la Diabetes y enfermedades metabólicas) (CIBERDEM), ISCIII Madrid Spain

Villarroya-Gombau F:
 Department of Biochemistry and Molecular Biology, Institute of Biomedicine University of Barcelona Barcelona Spain

 Biomedical Research Center (Red Fisiopatología de la Obesidad y Nutrición) (CIBEROBN), ISCIII Madrid Spain

Lerin C:
 Endocrinology Department Institut de Recerca Sant Joan de Déu Barcelona Spain

 Hospital Sant Joan de Déu Barcelona Spain

Sánchez-Infantes D:
 Department of Endocrinology and Nutrition Germans Trias i Pujol Research Institute Barcelona Spain

 Biomedical Research Center (Red Fisiopatología de la Obesidad y Nutrición) (CIBEROBN), ISCIII Madrid Spain
ISSN: 20552238





Obesity Science & Practice
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ, Estados Unidos America
Tipo de documento: Article
Volumen: 6 Número: 1
Páginas: 99-106
WOS Id: 000499788800001
ID de PubMed: 32128247
imagen Green Published, gold

MÉTRICAS